Prognosis of MECOM (EVI1)-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count
Authors:
- 19 March 2020
- journal article
- letter
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 61 (7) , 1756-1759
Abstract
(2020). Prognosis of MECOM (EVI1)-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count. Leukemia & Lymphoma. Ahead of Print.Keywords
This publication has 14 references indexed in Scilit:
- From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities?Blood Reviews, 2019
- EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcriptionNature Communications, 2018
- The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)/t(3;3)(q21;q26.2)Archives of Pathology & Laboratory Medicine, 2016
- Acute myeloid leukemia ontogeny is defined by distinct somatic mutationsBlood, 2015
- Clinical and genetic predictors of prognosis in myelodysplastic syndromesHaematologica, 2014
- Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group studyHaematologica, 2014
- Revised International Prognostic Scoring System for Myelodysplastic SyndromesBlood, 2012
- Frequent pathway mutations of splicing machinery in myelodysplasiaNature, 2011
- RUNX1Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study GroupJournal of Clinical Oncology, 2011
- Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 casesLeukemia, 2002